Should Amgen join the biopharma breakup party? Analyst says maybe

Save

Now that the Big Pharma breakup craze has moved down the drugmaker food chain to Baxter International, should Big Biotech jump on the trend? Maybe one of that group, an analyst suggests. As <em>Forbes</em> reports, Bernstein analyst Geoffrey Porges figures Amgen offers a decent opportunity for a breakup.